Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04388813 · ClinicalTrials.gov registry record
Predictors of Severe COVID-19 Outcomes
A clinical trial, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 494
- Enrollment target
NCT04388813: Completed study, sponsored by Verily Life Sciences.
NCT04388813 is a clinical trial that has completed, run by Verily Life Sciences. The registered enrollment target is 494 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04388813 has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 494 participants
- Enrollment target
Study Summary
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Primary Outcome
Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2021-09-23 |
What the finished NCT04388813 record still lists
NCT04388813 is an observational study that tracks outcomes without assigning an intervention. The registered 494 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04388813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04388813 about?
NCT04388813 is a clinical study titled "Predictors of Severe COVID-19 Outcomes". This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in pa...
What is the current status of trial NCT04388813?
This trial is currently completed. The enrollment target is 494 participants. The study started on 2020-05-28. Estimated completion is 2021-09-23.
Who is sponsoring clinical trial NCT04388813?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI